&w=3840&q=100)
40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives
The weight loss drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity read more
There have been at least 40 cases of unexpected pregnancies associated with weight loss drugs. Pixabay
British health authorities have issued a warning to women using weight-loss medications such as Ozempic, Wegovy and Mounjaro, urging them to use effective contraception after dozens of pregnancy reports linked to the drugs.
The Medicines and Healthcare products Regulatory Agency (MHRA) on Friday (May 6) released its first public safety alert addressing the use of weight-loss drugs and contraception. The agency said it had received 40 reports of pregnancies involving users of medications that include the active ingredients semaglutide or tirzepatide, The Guardian reported.
STORY CONTINUES BELOW THIS AD
Ozempic and Wegovy, which both contain semaglutide, mimic a gut hormone called GLP-1 that helps reduce appetite by slowing digestion and increasing insulin production. Mounjaro, which contains tirzepatide, also targets a second hormone involved in blood sugar and appetite control.
Though often referred to as 'weight-loss injections,' not all of the drugs are formally authorised for weight loss.
Drugs not advised during pregnancy or attempts to conceive
The MHRA said the drugs should not be taken during pregnancy, while trying to conceive, or while breastfeeding due to a lack of safety data. In some cases, the agency recommends that women continue contraception for up to two months after stopping the medication before attempting pregnancy.
Among the 40 reports, eight were associated with semaglutide and nine with liraglutide, which is found in the weight-loss drug Saxenda. Two cases were explicitly reported as unintended pregnancies.
Dr. Channa Jayasena, a reproductive endocrinologist at Imperial College Healthcare NHS Trust, said the drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity.
'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' he said. He also noted that the medications may interfere with the absorption of oral contraceptives due to delayed stomach emptying, although further research is needed.
Officials stress responsible use
Dr. Alison Cave, the MHRA's chief safety officer, warned that the medications should not be used as quick fixes for weight loss or for cosmetic purposes.
'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Cave said. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way.'
The MHRA said it has published updated guidance to help patients use the medications safely but emphasized that the advice should not replace consultation with a healthcare provider.
STORY CONTINUES BELOW THIS AD
Dr. Jayasena added that while the risks of GLP-1 drugs in pregnancy are not fully known, similar weight-loss interventions like surgery have been associated with higher miscarriage rates. 'So women are advised to do all they can to prevent pregnancy while taking GLP-1 drugs,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Monarch's health in a delicate state: Bombshell report reveals King Charles' cancer is incurable
In a development that is likely to intensify public concern over the British monarch's condition, a prominent royal report has stated that King Charles' cancer is considered incurable, though manageable, as mentioned in a report by Daily Beast. While the King, aged 76, continues to fulfill many of his royal duties, the disclosure is expected to reignite speculation about the long-term stability of the monarchy. Cancer May Be Lifelong Companion, Not Immediate Threat According to a report published by senior royal correspondent and Daily Telegraph associate editor Camilla Tominey, the King is expected to 'die with' cancer, not 'of' it — a subtle but significant distinction. Sources suggest that although His Majesty has responded to treatment, the illness remains a chronic condition rather than one from which full recovery is anticipated. Tominey notes that the monarch is undergoing a rigorous treatment regimen, which has allowed him to resume most of his public engagements, albeit with certain adjustments. The palace has not officially commented on the new claims, but aides have previously indicated that the King is 'on the other side' of the most critical phase of his health crisis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Container Houses Vietnam (Prices May Surprise You) Container House | Search ads Search Now Undo Public Life Resumes, But Behind-the-Scenes Concerns Remain Despite his diagnosis last year, King Charles has returned to a relatively active schedule. However, reports suggest that he will not be relocating to Buckingham Palace, as had been previously planned, largely due to his ongoing health challenges. Meanwhile, early discussions are reportedly underway for the King's 80th birthday celebrations in 2028 — a move palace officials say reflects cautious optimism about his condition. Live Events Family Tensions Resurface Amid Health Revelations The report also touches on the strained relationship between King Charles and his younger son, Prince Harry. In a recent BBC interview, the Duke of Sussex made an emotional appeal for reconciliation, stating, 'Life is precious. I don't know how much longer my father has', as per a report by Daily Beast. Prince Harry's remarks follow a contentious legal battle over his U.K. security arrangements, during which he expressed frustration that the King had distanced himself from discussions. He further claimed that palace insiders may prefer him 'dead,' citing concerns about his family's safety when visiting the United Kingdom. Tominey suggests that palace officials are quietly exploring the possibility of a public reunion between Charles and Harry at the 2027 Invictus Games in Birmingham. Such an event could serve as a meaningful backdrop for reconciliation, possibly involving Harry's children, Prince Archie and Princess Lilibet — both of whom the King reportedly has not seen since 2022. Palace Weighs Public Perception There is growing recognition within royal circles that the ongoing estrangement between father and son may be damaging the King's image. 'There is an awareness that the impasse cannot continue forever,' writes Tominey, 'not least if it starts to reflect badly on the King.' As concerns mount about the monarch's long-term health and family unity, the public and palace alike appear to be preparing for a future that, while not immediately alarming, is undeniably uncertain. FAQs What is the latest update on King Charles' cancer diagnosis? A recent report states that King Charles' cancer is incurable but manageable . Though not life-threatening in the immediate term, the condition is considered chronic, meaning he is expected to live with it for the rest of his life. Who reported this information about the King's health? The update was provided by Camilla Tominey, senior royal correspondent and associate editor of The Daily Telegraph , as reported in the Daily Beast .
First Post
6 hours ago
- First Post
40 women using weight-loss drugs see unexpected pregnancies; prompt UK's warning over contraceptives
The weight loss drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity read more There have been at least 40 cases of unexpected pregnancies associated with weight loss drugs. Pixabay British health authorities have issued a warning to women using weight-loss medications such as Ozempic, Wegovy and Mounjaro, urging them to use effective contraception after dozens of pregnancy reports linked to the drugs. The Medicines and Healthcare products Regulatory Agency (MHRA) on Friday (May 6) released its first public safety alert addressing the use of weight-loss drugs and contraception. The agency said it had received 40 reports of pregnancies involving users of medications that include the active ingredients semaglutide or tirzepatide, The Guardian reported. STORY CONTINUES BELOW THIS AD Ozempic and Wegovy, which both contain semaglutide, mimic a gut hormone called GLP-1 that helps reduce appetite by slowing digestion and increasing insulin production. Mounjaro, which contains tirzepatide, also targets a second hormone involved in blood sugar and appetite control. Though often referred to as 'weight-loss injections,' not all of the drugs are formally authorised for weight loss. Drugs not advised during pregnancy or attempts to conceive The MHRA said the drugs should not be taken during pregnancy, while trying to conceive, or while breastfeeding due to a lack of safety data. In some cases, the agency recommends that women continue contraception for up to two months after stopping the medication before attempting pregnancy. Among the 40 reports, eight were associated with semaglutide and nine with liraglutide, which is found in the weight-loss drug Saxenda. Two cases were explicitly reported as unintended pregnancies. Dr. Channa Jayasena, a reproductive endocrinologist at Imperial College Healthcare NHS Trust, said the drugs, by mimicking gut hormones, effectively reduce appetite and promote weight loss, which can in turn boost fertility in women with obesity. 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' he said. He also noted that the medications may interfere with the absorption of oral contraceptives due to delayed stomach emptying, although further research is needed. Officials stress responsible use Dr. Alison Cave, the MHRA's chief safety officer, warned that the medications should not be used as quick fixes for weight loss or for cosmetic purposes. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Cave said. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way.' The MHRA said it has published updated guidance to help patients use the medications safely but emphasized that the advice should not replace consultation with a healthcare provider. STORY CONTINUES BELOW THIS AD Dr. Jayasena added that while the risks of GLP-1 drugs in pregnancy are not fully known, similar weight-loss interventions like surgery have been associated with higher miscarriage rates. 'So women are advised to do all they can to prevent pregnancy while taking GLP-1 drugs,' he said.
&w=3840&q=100)
Business Standard
11 hours ago
- Business Standard
Diabetes and obesity management drug Mounjaro sees sales rise in India
Eli Lilly's diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven by increasing demand and a growing number of patients shifting to higher dosages, according to market research firm Pharmarack. In May, volume sales of the 5 mg dose grew by 2.5 times. The drug, launched in India on 20 March this year, is currently available in two injectable dosage forms — 2.5 and 5 milligrams (mg). It is prescribed primarily for patients who meet certain clinical criteria related to obesity and diabetes. Data suggests that both value and quantity sales of the 5 mg form more than doubled from April to May, outperforming the 2.5 mg dosage. Mounjaro 5 mg sales rose from 9,380 units in April (valued at ₹3.08 crore) to 22,940 units in May, valued at ₹7.53 crore. For the 2.5 mg form, demand growth was relatively muted — 19,350 units in May, up from 18,270 units in April. The sales value for May stood at ₹5.08 crore, up marginally from ₹4.8 crore the previous month. However, the steady growth in the 2.5 mg dosage indicates a consistent rise in new patients starting the drug. Patients typically begin treatment with the 2.5 mg dose, which is gradually escalated. 'The almost doubling of sales for the 5 mg form is because existing patients are upgrading to higher doses after four weeks, while new patients are also onboarding Mounjaro in good numbers,' said Sheetal Sapale, vice-president (commercial) at Pharmarack. Treatment with Mounjaro is typically initiated with the lowest available dosage (2.5 mg), administered subcutaneously once a week. 'This starting dose is usually maintained for the first four weeks to help the patient adjust and minimise potential side effects,' said Dr Sukhvinder Singh Saggu, director for minimal access, GI and bariatric surgery at CK Birla Hospital, Delhi. After this initial phase, the dose is commonly increased to 5 mg weekly, as weight-loss outcomes tend to be more pronounced at this level. Experts add that while the 2.5 mg dose helps initiate the process, many patients experience a plateau at that dosage, and shifting to 5 mg allows for more consistent and promising results. Doctors say inquiries for the drug have risen steadily, with Mounjaro now also being prescribed in select cases prior to bariatric surgery. Saggu said many new patients are actively inquiring about the drug, either as a new treatment option or as part of their ongoing weight management plans. 'Some of our existing patients, who were previously prescribed medications like Fenoglide, are now also being considered for Mounjaro as an alternative or add-on therapy,' he added. According to standard guidelines for obesity management medications (OMMs), a patient must have a Body Mass Index (BMI) over 27 with at least one obesity-related comorbidity, such as Type 2 diabetes, hypertension, or high cholesterol. However, doctors are also receiving inquiries from individuals who do not meet the medical criteria. 'We are strictly discouraging its use for cosmetic purposes or in patients who do not meet the clinical threshold,' Saggu said.
